CliffBio
small molecule

CYCLOPHOSPHAMIDE

CYCLOPHOSPHAMIDE

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYCLOPHOSPHAMIDE
Active ingredientCYCLOPHOSPHAMIDE
Strength500MG/2.5ML (200MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CYCLOPHOSPHAMIDE patent cliff — loss of exclusivity — | CliffBio